临床肝胆病杂志2024，Vol.40Issue(11)：2306-2314,9.DOI:10.12449/JCH241127
晚期肝细胞癌的系统治疗
Systemic therapy for advanced hepatocellular carcinoma
摘要
Abstract
Hepatocellular carcinoma(HCC)is one of the most common malignancies with high morbidity and mortality rates worldwide.With the advances in molecular biology and tumor immunology,molecular-targeted agents represented by tyrosine kinase inhibitors(such as sorafenib and lenvatinib)and immunotherapy represented by PD-1/PD-L1 monoclonal antibodies have brought hope for patients with advanced HCC.The combination of immunotherapy and anti-angiogenic therapy can further improve the treatment outcome of patients.In addition,the optimization and integration of stereotactic body radiotherapy,local treatment,and systemic treatment may maximize the benefits of patients.In the future,through a deep understanding of the heterogeneity of HCC,the development of precision molecular subtyping and individualized treatment,and the establishment of a multidisciplinary collaborative diagnosis and treatment system,systemic therapy is expected to achieve long-term management of advanced HCC.This article reviews the current status and advances in systemic therapy for advanced HCC.关键词
癌,肝细胞/精准医学/治疗学Key words
Carcinoma,Hepatocellular/Precision Medicine/Therapeutics引用本文复制引用
徐家豪,尹东旭,李宇辰,陈富杰,王明达,杨田..晚期肝细胞癌的系统治疗[J].临床肝胆病杂志,2024,40(11):2306-2314,9.基金项目
国家自然科学基金(81972726) （81972726）
上海市自然科学基金(22ZR1477900) National Natural Science Foundation of China(81972726) （22ZR1477900）
Natural Science Foundation of Shanghai(22ZR1477900) （22ZR1477900）
